“Tularemia Vaccine: Safety, Reactogenicity, "take" Skin Reactions, And Antibody Responses Following Vaccination With A New Lot Of The Francisella Tularensis Live Vaccine Strain - A Phase 2 Randomized Clinical Trial.”. Vaccine 35 (36). Vaccine: 4730-4737. doi:10.1016/j.vaccine.2017.07.024.
. 2017. “Cell Mediated Immune Responses Following Revaccination With An Influenza A/h5N1 Vaccine.”. Vaccine 34 (4). Vaccine: 547-554. doi:10.1016/j.vaccine.2015.11.055.
. 2016. “Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases The Duration Of T Cell Responses Induced By A Heterologous H5 Booster Vaccination.”. J Infect Dis 214 (7). J Infect Dis: 1020-9. doi:10.1093/infdis/jiw310.
. 2016. “Safety And Immunogenicity Of A Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, Stebvax.”. Clin Vaccine Immunol 23 (12). Clin Vaccine Immunol: 918-925. doi:10.1128/CVI.00399-16.
. 2016. “Norovirus Vaccine Against Experimental Human Gii.4 Virus Illness: A Challenge Study In Healthy Adults.”. J Infect Dis 211 (6). J Infect Dis: 870-8. doi:10.1093/infdis/jiu497.
. 2015. “Immunogenicity Of Avian Influenza A/anhui/01/2005(H5N1) Vaccine With Mf59 Adjuvant: A Randomized Clinical Trial.”. Jama 312 (14). Jama: 1420-8. doi:10.1001/jama.2014.12609.
. 2014. “A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate--Reactogenicity, Safety, And Immunogenicity In A Phase 1 Trial In Healthy Adults.”. J Infect Dis 210 (11). J Infect Dis: 1763-71. doi:10.1093/infdis/jiu337.
. 2014. “Immunogenicity And Safety Of Varying Dosages Of A Monovalent 2009 H1N1 Influenza Vaccine Given With And Without As03 Adjuvant System In Healthy Adults And Older Persons.”. J Infect Dis 206 (6). J Infect Dis: 811-20. doi:10.1093/infdis/jis427.
. 2012. “Phase 2 Assessment Of The Safety And Immunogenicity Of Two Inactivated Pandemic Monovalent H1N1 Vaccines In Adults As A Component Of The U.s. Pandemic Preparedness Plan In 2009.”. Vaccine 30 (28). Vaccine: 4240-8. doi:10.1016/j.vaccine.2012.04.044.
. 2012. “Norovirus Vaccine Against Experimental Human Norwalk Virus Illness.”. N Engl J Med 365 (23). N Engl J Med: 2178-87. doi:10.1056/NEJMoa1101245.
. 2011. “Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies And Antibody-Secreting Cells That Express Homing Receptors For Mucosal And Peripheral Lymphoid Tissues.”. J Infect Dis 202 (11). J Infect Dis: 1649-58. doi:10.1086/657087.
. 2010. “Safety And Immunogenicity Of A Subvirion Inactivated Influenza A/h5N1 Vaccine With Or Without Aluminum Hydroxide Among Healthy Elderly Adults.”. Vaccine 27 (37). Vaccine: 5091-5. doi:10.1016/j.vaccine.2009.06.057.
. 2009.